Hikma Pharmaceuticals (HIK)

 

HIK Share PerformanceMore

52 week high2,346.0 16/03/17
52 week low1,101.0 17/08/17
52 week change -1,016.0 (-47.06%)
4 week volume20,425,819 26/08/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 8069Q Hikma Pharmaceuticals Plc 14 September 2017 TR-1: S tandard form for notification of major holdings LONDON, 14 September 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75) , the fast-growing multinational pharmaceuticals group, announces as follows: NOTIFICATION OF MAJOR HOL...

Broker Forecast - Cantor Fitzgerald issues a broker note on Hikma Pharmaceuticals PLC

Cantor Fitzgerald today reaffirms its buy investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its price ...

Broker Forecast - Stifel issues a broker note on Hikma Pharmaceuticals PLC

Stifel today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to hold (from buy) and cut its p...

Holding(s) in Company

RNS Number: 9963O Hikma Pharmaceuticals Plc 25 August 2017 TR-1: Standard form for notification of major holdings LONDON, 25 August 2017 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK) (LEI: 549300BNS685UXH4JI75), the fast-growing multinational pharmaceuticals group, announces as follows: NOTIFICATION OF MAJOR HOLDINGS...

Broker Forecast - Barclays Capital issues a broker note on Hikma Pharmaceuticals PLC

Barclays Capital today reaffirms its overweight investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and cut its...

Broker Forecast - Citigroup issues a broker note on Hikma Pharmaceuticals PLC

Citigroup today reaffirms its neutral investment rating on Hikma Pharmaceuticals PLC (LON:HIK) and set its price target...

Broker Forecast - Goldman Sachs issues a broker note on Hikma Pharmaceuticals PLC

Goldman Sachs today downgrades its investment rating on Hikma Pharmaceuticals PLC (LON:HIK) to neutral (from buy...

Stockwatch: Is this a coiled spring or a falling knife?

It's likely private investors are eyeing this mid cap up but sitting on their hands for now. This could be of interest to vigilan...

Fundamental DataMore

P/E ratio17.186
EPS66.5
Dividend yield2.887 %

Latest discussion posts More

  • Wake up everyone - perspective!

    Hello all. Let's not forget this business earns around two thirds of it's profit from injectables. Much too large a portion to be caught up in the generics downturn to the ...
    24-Aug-2017
    middler2
  • Re: raising prices

    Yes they can charge what they like, BUT the healthcare insurance companies can direct that a much cheaper alternative is used/supplied. The price hike strategy can backfire ...
    22-Aug-2017
    Proverbs 26 vs 5
  • raising prices

    Are they allowed to raise prices 430% This seems excessive.
    21-Aug-2017
    susanne9

Users' HoldingsMore

Users who hold Hikma Pharmaceuticals also hold..
LLOYDS GRP.37%
GLAXOSMITHKLINE28%
BP24%
RDS 'B'24%
BT GROUP23%

Codes & Symbols

ISINGB00B0LCW083
SymbolsHIK, LSE:HIK, HIK.L, HIK:LN, LON:HIK, XLON:HIK